GlaxoSmithKline has announced that both the Arnuity Ellipta fluticasone furoate DPI and the Incruse Ellipta umeclidinium bromide DPI are now available in the US. Arnuity Ellipta was approved by the FDA in August 2014 for the treatment of asthma. The FDA approved Incruse Ellipta for the treatment of COPD in April 2014.
GSK Senior VP of the US Respiratory Business Unit Jorge Bartolome said, “We’re excited to share this news with patients. Forty years after the launch of our first respiratory therapy, we remain committed to innovation and helping a wide range of appropriate patients. These are the third and fourth respiratory products we’ve introduced since October 2013 in our patented Ellipta inhaler.”
The previous Ellipta launches were Breo Ellipta in October 2013 and Anoro Ellipta in April 2014.
Read the GSK press release.
